Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background & Aims</h3><p>Worldwide, Nonalcoholic fatty liver disease (NAFLD) prevalence increases rapidly and becomes a major global health problem. Tumor necrosis factor‐α‐induced protein 8‐like 2 (TIPE2) plays a protective role in a cluster of liver diseases, such as autoimmune hepatitis, hepatitis B, and hepatocellular carcinoma. But the function of TIPE2 in NAFLD remained unknown. Here, we investigated the role of TIPE2 in the development of NAFLD.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Approach & Results</h3><p>Our study found in vitro overexpression or knockout of TIPE2 significantly ameliorated or aggravated lipid accumulation and inflammation in hepatocytes exposed to metabolic stimulation, respectively. Consistently, in vivo hepatic steatosis, insulin resistance, inflammation, and fibrosis were alleviated in hepatic TIPE2 transgenic mice but exaggerated in hepatic TIPE2 knockout mice treated by metabolic challenges. RNA sequencing revealed TIPE2 was significantly associated with the mitogen‐activated protein kinase (MAPK) pathway. Mechanistic experiments demonstrated that TIPE2 bound with transforming growth factor‐beta‐activated kinase 1 (TAK1) under metabolic stress, prevented tumor necrosis factor receptor‐associated factor 6 (TRAF6)‐mediated TAK1 ubiquitination and subsequently inhibited the phosphorylation and activation of TAK1‐c‐Jun NH2‐terminal kinase (JNK)/p38 signaling. Further investigation showed that blocking the activity of TAK1 reversed the worsening of hepatic metabolic disorders and inflammation in TIPE2‐HKO hepatocytes and mice treated with metabolic stimulation.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>TIPE2 suppresses NAFLD advancement by blocking TAK1‐JNK/p38 pathway and is a promising target molecule for NAFLD therapy.</p></section>

Tumor Necrosis Factor α–Induced Protein 8–Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta–Activated Kinase 1 Activation

Tnf-Alpha-Induce Protein 8-Like 1 Inhibits Hepatic Steatosis, Inflammation, And Fibrosis By Suppressing Polyubiquitination Of Apoptosis Signal-Regulating Kinase 1

Terf2ip Deficiency Accelerates Non-Alcoholic Steatohepatitis Through Regulating Lipophagy and Fatty Acid Oxidation Via Sirt1/AMPK Pathway

Tumor Progression Locus 2 in Hepatocytes Potentiates Both Liver and Systemic Metabolic Disorders in Mice

TIPE2 protein restrains invariant NKT activation and protects against immune-mediated hepatitis in mice

Allyl Isothiocyanate Ameliorates Lipid Accumulation and Inflammation in Nonalcoholic Fatty Liver Disease Via the Sirt1/AMPK and NF-κB Signaling Pathways.

Leukocyte Cell-Derived Chemotaxin 2 Promotes the Development of Nonalcoholic Fatty Liver Disease Through STAT-1 Pathway in Mice.

Insulin-like Growth Factor Binding Protein 1 Ameliorates Lipid Accumulation and Inflammation in Nonalcoholic Fatty Liver Disease

Betaine Alleviates Nonalcoholic Fatty Liver Disease (NAFLD) Via a Manner Involving BHMT/FTO/m6A/ PGC1α Signaling.

Tripartite motif 38 alleviates the pathological process of NAFLD/NASH by promoting TAB2 degradation

Hepatic Regulator of G Protein Signaling 5 Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Transforming Growth Factor Beta–Activated Kinase 1–c‐Jun‐N‐Terminal Kinase/p38 Signaling

Milk Fat Globule–Epidermal Growth Factor–Factor 8 Improves Hepatic Steatosis and Inflammation

Neurotropin Inhibits Lipid Accumulation by Maintaining Mitochondrial Function in Hepatocytes via AMPK Activation

TET1 Promotes Fatty Acid Oxidation and Inhibits NAFLD Progression by Hydroxymethylation of PPARα Promoter

TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice

TAF and TDF attenuate liver fibrosis through NS5ATP9, TGFβ1/Smad3, and NF-κB/NLRP3 inflammasome signaling pathways

Transcription factor EB inhibits non-alcoholic fatty liver disease through fibroblast growth factor 21

Tipe2 Suppresses the Tumorigenesis, Growth and Metastasis of Breast Cancer Via Inhibition of the Akt and P38 Signaling Pathways

Hepatoprotective effect of Typhaneoside on non-alcoholic fatty liver disease via farnesoid X receptor in vivo and in vitro

CX08005, a Protein Tyrosine Phosphatase 1B Inhibitor, Attenuated Hepatic Lipid Accumulation and Microcirculation Dysfunction Associated with Nonalcoholic Fatty Liver Disease

Thyme (Thymus quinquecostatus Celak) Polyphenol-Rich Extract (TPE) Alleviates HFD-Induced Liver Injury in Mice by Inactivating the TLR4/NF-κB Signaling Pathway through the Gut–Liver Axis